Sung Ji Nam
Stock Analyst at Scotiabank
(3.25)
# 963
Out of 4,667 analysts
60
Total ratings
48.65%
Success rate
2.82%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Maintains: Sector Outperform | $50 → $54 | $41.11 | +31.35% | 4 | Nov 19, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $7 → $6 | $1.72 | +248.84% | 4 | Nov 11, 2024 | |
| VCYT Veracyte | Maintains: Sector Outperform | $40 → $44 | $39.20 | +12.24% | 4 | Nov 8, 2024 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $37 → $44 | $28.45 | +54.66% | 5 | Nov 6, 2024 | |
| CDNA CareDx | Maintains: Buy | $40 → $35 | $22.37 | +56.46% | 4 | Nov 5, 2024 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $83 → $88 | $68.72 | +28.06% | 1 | Oct 31, 2024 | |
| BDSX Biodesix | Initiates: Sector Outperform | $3 | $1.19 | +152.10% | 1 | Sep 16, 2024 | |
| BNGO Bionano Genomics | Downgrades: Sector Perform | $6 → $1 | $0.21 | +377.55% | 5 | Aug 28, 2024 | |
| ILMN Illumina | Maintains: Sector Outperform | $176 → $164 | $131.68 | +24.54% | 9 | Aug 15, 2024 | |
| MYGN Myriad Genetics | Maintains: Sector Outperform | $29 → $34 | $15.30 | +122.22% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $52.70 | +32.83% | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $7.74 | -22.48% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $36 | $30.68 | +17.34% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $4.42 | +239.37% | 1 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $718 | $512.84 | +40.00% | 11 | Feb 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $17.28 | - | 3 | Nov 24, 2020 |
Twist Bioscience
Nov 19, 2024
Maintains: Sector Outperform
Price Target: $50 → $54
Current: $41.11
Upside: +31.35%
Pacific Biosciences of California
Nov 11, 2024
Maintains: Sector Outperform
Price Target: $7 → $6
Current: $1.72
Upside: +248.84%
Veracyte
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $39.20
Upside: +12.24%
Castle Biosciences
Nov 6, 2024
Maintains: Sector Outperform
Price Target: $37 → $44
Current: $28.45
Upside: +54.66%
CareDx
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $22.37
Upside: +56.46%
Bio-Techne
Oct 31, 2024
Maintains: Sector Outperform
Price Target: $83 → $88
Current: $68.72
Upside: +28.06%
Biodesix
Sep 16, 2024
Initiates: Sector Outperform
Price Target: $3
Current: $1.19
Upside: +152.10%
Bionano Genomics
Aug 28, 2024
Downgrades: Sector Perform
Price Target: $6 → $1
Current: $0.21
Upside: +377.55%
Illumina
Aug 15, 2024
Maintains: Sector Outperform
Price Target: $176 → $164
Current: $131.68
Upside: +24.54%
Myriad Genetics
Aug 13, 2024
Maintains: Sector Outperform
Price Target: $29 → $34
Current: $15.30
Upside: +122.22%
Jun 27, 2024
Initiates: Sector Outperform
Price Target: $70
Current: $52.70
Upside: +32.83%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $7.74
Upside: -22.48%
Jan 5, 2023
Initiates: Sector Outperform
Price Target: $36
Current: $30.68
Upside: +17.34%
Jan 5, 2023
Initiates: Sector Outperform
Price Target: $15
Current: $4.42
Upside: +239.37%
Feb 2, 2022
Maintains: Buy
Price Target: $718
Current: $512.84
Upside: +40.00%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $17.28
Upside: -